Perceptive Informatics rolled out a pair of new imaging technologies aimed at enhancing its cardiology trial offering.
The Parexel International Corp. (PRXL) subsidiary adopted Hermes Medical Solutions’ nuclear medicine software suite and Invia’s Corridor4DM nuclear cardiac quantification and imaging solution.
Perceptive said the additions allow it to integrate positron emission tomography, single-photon-emission computed tomography and multi-gated acquisition scan data from cardiology trials. The Hermes product assembles images from any scanner and converts them into a standardized format for processing and review. The Invia product allows researchers to review and quantify cardiac perfusion, function and anatomy in three dimensions.
Parexel posted net income of $12.4 million on sales of $307.5 million during the three months ended Sept. 30, compared with net income of $13.6 million on sales of $319.6 million during the same period last year — declines of 3.8 percent and 8.7 percent, respectively, for its fiscal 2010 first quarter.
Chairman and CEO Josef von Rickenbach said the company is planning a major restructuring effort, aimed at better leveraging its global resources. Parexel said it expects to take a $30 million charge related to the move during its second quarter, to cover the cost of layoffs and “facility restructuring.”
